Gone are the days of relying only on universal systemic treatment. These are the days of precision oncology. Where optimal outcomes come with fewer obstacles, clinically actionable data serves as your compass, and therapy options that match your patient’s needs are ready to make an impact.
Ultra-comprehensive genomic profiling, utilizing whole exome and whole transcriptome sequencing (WES/WTS), to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent solid tumors.